PBGENE-HBV

Phase 1Biologic

PPrecision BioSciences, Inc.

PBGENE-HBV is one of 4 biologic programs targeting Hepatitis B, Chronic. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis B, ChronicRecruiting

Hepatitis B, ChronicPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Hepatitis B, Chronic

#DrugCompanyPhaseTrials

Bepirovirsen

GSK

Phase 2

1 2

AHB-137

AAusper Biopharma Co., Ltd.

Phase 2

3 3

PBGENE-HBV

PPrecision BioSciences, Inc.

Phase 1

1 4

Pegylated Interferon-Alpha (IFN)

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Hepatitis B, Chronic

NCT06680232

Q2 2040

Not yet recruiting

Observational Study

NCT07254208

Clinical

Trials by Indication[1]

Observational Study1 trial

A Long-term Observational Study in Participants Who Have Received PBGENE-HBV

Not yet recruiting·PPrecision BioSciences, Inc.··NCT07254208·45 enrolled

Hepatitis B, Chronic1 trial

A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B)

Recruiting·PPrecision BioSciences, Inc.·Phase 1·NCT06680232·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PBGENE-HBV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PBGENE-HBV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PBGENE-HBV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Precision BioSciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PPrecision BioSciences, Inc.

PBGENE-HBV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2040

Trials by Indication[1]

Observational Study1 trial

Hepatitis B, Chronic1 trial

References

Drug Info

Quick Facts

Related News